Other Transcription Factors – Page 2 – Structure-Based Drug Design of ALK inhibitors in pre-clinical models

Section were incubated in 4 overnight?C with antibodies against CA9 (1:200, Abcam), Compact disc10 (1:30, Dako), Compact disc44 (1:400, BD biosciences), CXCR4 (1:200, Abcam), MET (1:50, Cell Signaling Technology), VCAM1 (1:250, Abcam), E-Cadherin (1:1000, BD biosciences), Epcam (1:500, Abcam), Ki-67 (1:200, Thermo Fisher), or JAG1 (1:200, Atlas Antibodies) major antibodies and Alexa-conjugated supplementary antibodies (1:200, Dianova)

By moca09Posted on December 29, 2021Posted in Other Transcription Factors

Section were incubated in 4 overnight?C with antibodies against CA9 (1:200, Abcam), Compact disc10 (1:30, Dako), Compact disc44 (1:400, BD biosciences), CXCR4 (1:200, Abcam), MET (1:50, Cell Signaling Technology), VCAM1 (1:250, Abcam), E-Cadherin (1:1000, BD biosciences), Epcam (1:500, Abcam), Ki-67 (1:200, Thermo Fisher), or JAG1 (1:200, Atlas Antibodies) major antibodies and Alexa-conjugated supplementary antibodies (1:200, […]

A375R cells were generated by continuous selective culture in vemurafenib; immunoblot-detection verified PDGFR-upregulation in these cells, a recognised signature molecular modification quality of vemurafenib-resistant melanoma cells (Body 6B) [19]

By moca09Posted on November 13, 2021Posted in Other Transcription Factors

A375R cells were generated by continuous selective culture in vemurafenib; immunoblot-detection verified PDGFR-upregulation in these cells, a recognised signature molecular modification quality of vemurafenib-resistant melanoma cells (Body 6B) [19]. iodide movement cytometry, and PMS-induced cell loss of life was suppressed by antioxidant (NAC) or pan-caspase inhibitor (zVAD-fmk) cotreatment. Gene appearance array evaluation in A375 melanoma […]